![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FBXO3 |
Gene summary for FBXO3 |
![]() |
Gene information | Species | Human | Gene symbol | FBXO3 | Gene ID | 26273 |
Gene name | F-box protein 3 | |
Gene Alias | FBA | |
Cytomap | 11p13 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q49AF1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26273 | FBXO3 | LZE3D | Human | Esophagus | HGIN | 3.90e-03 | 6.34e-01 | 0.0668 |
26273 | FBXO3 | LZE4T | Human | Esophagus | ESCC | 3.00e-09 | 3.26e-01 | 0.0811 |
26273 | FBXO3 | LZE7T | Human | Esophagus | ESCC | 4.84e-04 | 2.36e-01 | 0.0667 |
26273 | FBXO3 | LZE8T | Human | Esophagus | ESCC | 8.73e-07 | 1.86e-01 | 0.067 |
26273 | FBXO3 | LZE20T | Human | Esophagus | ESCC | 1.52e-04 | 3.31e-02 | 0.0662 |
26273 | FBXO3 | LZE24T | Human | Esophagus | ESCC | 3.13e-16 | 2.84e-01 | 0.0596 |
26273 | FBXO3 | P2T-E | Human | Esophagus | ESCC | 6.22e-16 | 2.98e-01 | 0.1177 |
26273 | FBXO3 | P4T-E | Human | Esophagus | ESCC | 6.01e-09 | 1.35e-01 | 0.1323 |
26273 | FBXO3 | P5T-E | Human | Esophagus | ESCC | 1.45e-05 | -4.58e-03 | 0.1327 |
26273 | FBXO3 | P8T-E | Human | Esophagus | ESCC | 1.35e-23 | 4.06e-01 | 0.0889 |
26273 | FBXO3 | P9T-E | Human | Esophagus | ESCC | 1.32e-05 | 1.47e-01 | 0.1131 |
26273 | FBXO3 | P10T-E | Human | Esophagus | ESCC | 3.40e-22 | 2.80e-01 | 0.116 |
26273 | FBXO3 | P11T-E | Human | Esophagus | ESCC | 4.16e-13 | 4.76e-01 | 0.1426 |
26273 | FBXO3 | P12T-E | Human | Esophagus | ESCC | 1.44e-23 | 4.33e-01 | 0.1122 |
26273 | FBXO3 | P15T-E | Human | Esophagus | ESCC | 3.03e-12 | 2.93e-01 | 0.1149 |
26273 | FBXO3 | P16T-E | Human | Esophagus | ESCC | 8.27e-16 | 2.58e-01 | 0.1153 |
26273 | FBXO3 | P17T-E | Human | Esophagus | ESCC | 3.82e-05 | 1.68e-01 | 0.1278 |
26273 | FBXO3 | P19T-E | Human | Esophagus | ESCC | 6.17e-03 | 2.14e-01 | 0.1662 |
26273 | FBXO3 | P20T-E | Human | Esophagus | ESCC | 1.61e-14 | 2.37e-01 | 0.1124 |
26273 | FBXO3 | P21T-E | Human | Esophagus | ESCC | 7.86e-16 | 3.36e-01 | 0.1617 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
GO:007138317 | Prostate | Tumor | cellular response to steroid hormone stimulus | 76/3246 | 204/18723 | 7.73e-12 | 6.16e-10 | 76 |
GO:190165418 | Prostate | Tumor | response to ketone | 70/3246 | 194/18723 | 2.69e-10 | 1.48e-08 | 70 |
GO:003196017 | Prostate | Tumor | response to corticosteroid | 57/3246 | 167/18723 | 1.11e-07 | 2.94e-06 | 57 |
GO:005138417 | Prostate | Tumor | response to glucocorticoid | 52/3246 | 148/18723 | 1.38e-07 | 3.50e-06 | 52 |
GO:007138514 | Prostate | Tumor | cellular response to glucocorticoid stimulus | 25/3246 | 56/18723 | 1.82e-06 | 3.19e-05 | 25 |
GO:007138414 | Prostate | Tumor | cellular response to corticosteroid stimulus | 26/3246 | 61/18723 | 3.31e-06 | 5.41e-05 | 26 |
GO:190165512 | Prostate | Tumor | cellular response to ketone | 33/3246 | 96/18723 | 4.19e-05 | 4.76e-04 | 33 |
GO:004350211 | Prostate | Tumor | regulation of muscle adaptation | 33/3246 | 98/18723 | 6.69e-05 | 7.18e-04 | 33 |
GO:009025713 | Prostate | Tumor | regulation of muscle system process | 66/3246 | 252/18723 | 2.54e-04 | 2.13e-03 | 66 |
GO:000301214 | Prostate | Tumor | muscle system process | 105/3246 | 452/18723 | 7.44e-04 | 5.14e-03 | 105 |
GO:004350011 | Prostate | Tumor | muscle adaptation | 35/3246 | 121/18723 | 1.08e-03 | 6.97e-03 | 35 |
GO:007154812 | Prostate | Tumor | response to dexamethasone | 15/3246 | 39/18723 | 1.42e-03 | 8.80e-03 | 15 |
GO:007154912 | Prostate | Tumor | cellular response to dexamethasone stimulus | 12/3246 | 29/18723 | 2.02e-03 | 1.16e-02 | 12 |
GO:004854528 | Skin | AK | response to steroid hormone | 73/1910 | 339/18723 | 4.51e-10 | 5.24e-08 | 73 |
GO:007138326 | Skin | AK | cellular response to steroid hormone stimulus | 46/1910 | 204/18723 | 1.79e-07 | 7.37e-06 | 46 |
GO:190165425 | Skin | AK | response to ketone | 43/1910 | 194/18723 | 7.32e-07 | 2.49e-05 | 43 |
GO:003196025 | Skin | AK | response to corticosteroid | 37/1910 | 167/18723 | 4.28e-06 | 1.05e-04 | 37 |
GO:005138425 | Skin | AK | response to glucocorticoid | 33/1910 | 148/18723 | 1.20e-05 | 2.46e-04 | 33 |
GO:007138510 | Skin | AK | cellular response to glucocorticoid stimulus | 16/1910 | 56/18723 | 1.02e-04 | 1.34e-03 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FBXO3 | SNV | Missense_Mutation | c.85G>A | p.Asp29Asn | p.D29N | Q9UK99 | protein_coding | tolerated(0.29) | benign(0.137) | TCGA-A2-A0YG-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
FBXO3 | SNV | Missense_Mutation | rs757358495 | c.251C>G | p.Ser84Cys | p.S84C | Q9UK99 | protein_coding | tolerated(0.08) | benign(0.339) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FBXO3 | SNV | Missense_Mutation | c.55N>A | p.Asp19Asn | p.D19N | Q9UK99 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
FBXO3 | SNV | Missense_Mutation | c.1269G>T | p.Met423Ile | p.M423I | Q9UK99 | protein_coding | tolerated_low_confidence(0.45) | benign(0) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
FBXO3 | SNV | Missense_Mutation | novel | c.1062N>G | p.Ile354Met | p.I354M | Q9UK99 | protein_coding | deleterious(0.01) | possibly_damaging(0.837) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
FBXO3 | insertion | Nonsense_Mutation | novel | c.1062_1063insTAA | p.Ile354_Ile355insTer | p.I354_I355ins* | Q9UK99 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
FBXO3 | SNV | Missense_Mutation | rs138194845 | c.1406N>A | p.Arg469His | p.R469H | Q9UK99 | protein_coding | deleterious_low_confidence(0) | benign(0.001) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FBXO3 | SNV | Missense_Mutation | c.312G>T | p.Lys104Asn | p.K104N | Q9UK99 | protein_coding | deleterious(0.03) | benign(0.15) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FBXO3 | SNV | Missense_Mutation | novel | c.276N>G | p.His92Gln | p.H92Q | Q9UK99 | protein_coding | tolerated(0.29) | benign(0.129) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FBXO3 | SNV | Missense_Mutation | c.509G>A | p.Arg170His | p.R170H | Q9UK99 | protein_coding | deleterious(0.01) | possibly_damaging(0.869) | TCGA-AG-A025-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |